CN115003686A - 用于抗冠状病毒感染的药物及其应用 - Google Patents

用于抗冠状病毒感染的药物及其应用 Download PDF

Info

Publication number
CN115003686A
CN115003686A CN202180010229.1A CN202180010229A CN115003686A CN 115003686 A CN115003686 A CN 115003686A CN 202180010229 A CN202180010229 A CN 202180010229A CN 115003686 A CN115003686 A CN 115003686A
Authority
CN
China
Prior art keywords
polypeptide
seq
substituted
functionally equivalent
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010229.1A
Other languages
English (en)
Inventor
薛彤彤
赵栋
肖亮
戚建英
喻海旻
龙虎
刘登念
沈利
赵忠琼
林丽洋
刘晨
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN115003686A publication Critical patent/CN115003686A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供了用于抗冠状病毒感染的多肽及其应用，具体而言，提供了抗冠状病毒感染的多肽及其衍生物、立体异构体、药学上可接受的盐或功能等价的变体，编码多肽的核酸分子，制备它们的方法，以及包含它们的药物组合物(例如药物制剂)。进一步提供了该多肽及其衍生物、立体异构体、药学上可接受的盐或功能等价的变体在预防和/或治疗冠状病毒感染相关疾病中的用途，以及在制备预防和/或治疗冠状病毒感染相关疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN202180010229.1A 2020-02-21 2021-02-05 用于抗冠状病毒感染的药物及其应用 Pending CN115003686A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010108555 2020-02-21
CN2020101085553 2020-02-21
PCT/CN2021/075497 WO2021164576A1 (zh) 2020-02-21 2021-02-05 用于抗冠状病毒感染的药物及其应用

Publications (1)

Publication Number Publication Date
CN115003686A true CN115003686A (zh) 2022-09-02

Family

ID=77390418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010229.1A Pending CN115003686A (zh) 2020-02-21 2021-02-05 用于抗冠状病毒感染的药物及其应用

Country Status (2)

Country Link
CN (1) CN115003686A (zh)
WO (1) WO2021164576A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235784A1 (en) * 2021-10-22 2023-04-27 Wisconsin Alumni Research Foundation Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity

Also Published As

Publication number Publication date
WO2021164576A1 (zh) 2021-08-26

Similar Documents

Publication Publication Date Title
EP1989220B1 (en) Hiv fusion inhibitor peptides with improved biological properties
EP2858661B1 (en) Stabilized antiviral fusion helices
US7335727B2 (en) Pharmaceutical used for treating HIV infection, the composition and uses thereof
CN111643656B (zh) 广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用
KR20220123294A (ko) 폴리펩티드, 이의 제조방법 및 용도
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
KR20100016142A (ko) 항바이러스 펩티드 치료제 전달용 신규 제제
CN115003686A (zh) 用于抗冠状病毒感染的药物及其应用
US20100261876A1 (en) Novel methods of synthesis for therapeutic antiviral peptides
CN115772227A (zh) 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
CN116444644A (zh) 一种广谱病毒膜融合抑制剂及其制备方法和用途
CN113292638A (zh) 用于抗冠状病毒感染的多肽药物及其方法和应用
CN112694526B (zh) 一种白细胞介素29突变体蛋白
US11834480B2 (en) Protein inhibitors with reduced immunogenicity and resistance to degradation, and methods for their preparation and use
CN115724919B (zh) 强效抑制艾滋病病毒及其耐药毒株的新型膜融合抑制剂及其药物用途
US20230235301A1 (en) Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis
TW200427697A (en) Pegylated t1249 polypeptide
WO2022232567A2 (en) Cyclic peptide inhibitors of usp22
JP2023527048A (ja) インターロイキン２９変異体タンパク質
US20210395306A1 (en) Polypeptides for the treatment of stress, immunoreaction and stroke syndromes
CN115770291A (zh) 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
CN115968291A (zh) 聚乙二醇化干扰素tau及其组合物和方法
US20070003565A1 (en) Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination